XNAS
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -2.51 | -2.93 | -16.73% | $6.9M | ❌ Miss | -5.03% | +1.06% | — |
| 2026-03-12 | Q4 2025 | -3.03 | -3.98 | -31.35% | $5.4M | ❌ Miss | +1.04% | +17.60% | -6.94% |
| 2025-11-10 |
| Q3 2025 |
| -3.09 |
| -3.59 |
| -16.18% |
| $3.3M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -2.37 | -3.86 | -62.87% | $2.0M | ❌ Miss | +0.64% | -10.90% | -39.98% |
| 2025-03-18 | Q4 2024 | -768.00 | -9.77 | +98.73% | $2.6M | ✅ Beat | -19.78% | +45.01% | -23.48% |
| 2024-08-16 | Q2 2024 | -720.00 | -1928.00 | -167.78% | $2.2M | ❌ Miss | -0.54% | -24.01% | -67.03% |
| 2024-05-13 | Q1 2024 | -1248.00 | -576.00 | +53.85% | $2.5M | ✅ Beat | +5.20% | +11.05% | -79.73% |
| 2024-04-01 | Q4 2023 | -5248.00 | -2752.00 | +47.56% | $3.8M | ✅ Beat | +0.37% | -2.32% | -6.79% |
Showing last 8 quarters.